Written answers
Thursday, 28 February 2019
Department of Health
Medicinal Products Reimbursement
Lisa Chambers (Mayo, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
157. To ask the Minister for Health the detail of the recommendation the Rare Disease Technical Review Committee gave on Spinraza, that is, to reimburse the drug; and if he will make a statement on the matter. [10112/19]
Lisa Chambers (Mayo, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
158. To ask the Minister for Health the detail of the recommendation the HSE drugs group gave on Spinraza to reimburse the drug; and if he will make a statement on the matter. [10113/19]
Lisa Chambers (Mayo, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
159. To ask the Minister for Health the detail of the recommendation the HSE Leadership Team gave on Spinraza to reimburse the drug; and if he will make a statement on the matter. [10114/19]
Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source
I propose to take Questions Nos. 157 to 159, inclusive, together.
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for the pricing and reimbursement of medicines; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.
No comments